A COHORT STUDY OF SECOND PRIMARY TUMORS FOLLOWING CHEMOTHERAPY FOR GESTATIONAL TROPHOBLASTIC DISEASE

ICR 198305-0925-003

OMB: 0925-0205

Federal Form Document

Forms and Documents
Document
Name
Status
No forms / supporting documents in this ICR. Check IC Document Collections.
ICR Details
0925-0205 198305-0925-003
Historical Active
HHS/NIH
A COHORT STUDY OF SECOND PRIMARY TUMORS FOLLOWING CHEMOTHERAPY FOR GESTATIONAL TROPHOBLASTIC DISEASE
New collection (Request for a new OMB Control Number)   No
Regular
Approved without change 06/23/1983
Retrieve Notice of Action (NOA) 05/03/1983
  Inventory as of this Action Requested Previously Approved
01/31/1985 01/31/1985
2,686 0 0
348 0 0
0 0 0

RECENT STUDIES SUGGEST THAT CERTAIN DRUGS USED TO TREAT CANCER MAY BE CARCINOGENIC THEMSELVES. AN EPIDEMIOLOGIC INVESTIGATION OF WOMEN WITH TROPHOBLASTIC DISEASE WHO RECEIVED METHOTREXATE OR ACTINOMYCIN-D IS PLANNED. AFTER CLINIC RECORD ABSTRACTION, FOLLOW-UP QUESTIONNARIES WILL BE SENT TO PATIENTS, NEXT-OF-KIN, AND PHYSICIANS, TO ASCERTAIN THE OCCURRENCE OF 2ND PRIMARY NEOPLASMS.

None
None


No

1
IC Title Form No. Form Name
A COHORT STUDY OF SECOND PRIMARY TUMORS FOLLOWING CHEMOTHERAPY FOR GESTATIONAL TROPHOBLASTIC DISEASE

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 2,686 0 0 2,686 0 0
Annual Time Burden (Hours) 348 0 0 348 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
No

$0
No
No
Uncollected
Uncollected
Uncollected
Uncollected

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/03/1983


© 2024 OMB.report | Privacy Policy